Abstract
Abstract Neuroleptic malignant syndrome (NMS) is a rare but life-threatening side effect of antipsychotic agents. Although the incidence of NMS is rare, it is essential to recognize it at an early stage and take the necessary precautions to prevent mortality and morbidity. Along with the treatment of NMS, the challenge is to treat the concomitant psychiatric symptoms, which become difficult to manage. There are no fixed guidelines or any data available regarding restarting of neuroleptics in a patient who has recovered from NMS. This case series is a set of three cases that reviews the differences in sociodemographic data, clinical presentation, management, and trial of rechallenge of psychotropics in patients with symptoms suggestive of NMS in a tertiary care hospital.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
